IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Paradigm Biopharmaceuticals Limited
Paradigm Biopharma is a Public Company that generates the majority of its income from the Pharmaceutical Product Manufacturing industry. In 2025 the company generated total revenue of $6,942,000 including sales and other revenue. The exact number of employees for this organisation is not available. The Chief Executive of Paradigm Biopharma is Mr Paul Rennie whose official title is Chairman & Managing Director. The Chairman of Paradigm Biopharma is Mr Paul Rennie whose official title is Chairman & Managing Director. Paradigm Biopharmaceuticals Limited is a drug repurposing company. The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications and repurposing that drug in a new patented therapeutic application. Paradigm Biopharmaceuticals Limited's current commercial focus is the repurposing of Pentosan Polysulfate Sodium (PPS) for the treatment of Osteoarthritis. The company have advanced to phase 3 trials in this space and are addressing all aspects of the disease: inflammation, pain, and regeneration.
Access this data your way
The Paradigm Biopharmaceuticals Limited Industry analysis is available in multiple formats to fit seamlessly into your workflow.
API Data Delivery
Feed trusted, human-driven industry intelligence straight into your platform.
Integrations
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
What's included in this industry analysis
IBISWorld's research coverage on the Paradigm Biopharmaceuticals Limited includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Company Details
What’s this enterprise profile about?
Paradigm Biopharmaceuticals Limited, trading as Paradigm Biopharma, operates under the ABN 94 169 346 963 and was incorporated on 02 May 2014. Paradigm Biopharmaceuticals Limited trades on the Australian Securities Exchange under the ticker code ASX:PAR. Paradigm Biopharmaceuticals Limited primarily operates in the Pharmaceutical Product Manufacturing industry in Australia.
Key Personnel
What’s included in the Key Personnel chapter?
The Key Personnel chapter outlines the principal leadership positions within Paradigm Biopharmaceuticals Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
Financials
What’s included in the Financials chapter?
The Financials chapter presents Paradigm Biopharmaceuticals Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
Growth & Ratios
What’s included in the Growth & Rations chapter?
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
Operating Segments
What’s included in the Operating Segments chapter?
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Paradigm Biopharmaceuticals Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
Competitor Benchmarking
What’s included in the Competitor Benchmarking chapter?
The Competitor Benchmarking chapter includes a comparative assessment of Paradigm Biopharmaceuticals Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
Shareholders
What’s included in the Shareholders chapter?
The Shareholders chapter provides a breakdown of the ownership structure of Paradigm Biopharmaceuticals Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
Subsidiaries
What’s included in the Subsidiaries chapter?
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Paradigm Biopharmaceuticals Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
History
What’s included in the History chapter?
The History chapter presents a overview of Paradigm Biopharmaceuticals Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
Trusted by industry professionals
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Frequently Asked Questions
What is Paradigm Biopharmaceuticals Limited?
Paradigm Biopharmaceuticals Limited is a drug repurposing company. The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications and repurposing that drug in a new patented therapeutic application. Paradigm Biopharmaceuticals Limited's current commercial focus is the repurposing of Pentosan Polysulfate Sodium (PPS) for the treatment of Osteoarthritis. The company have advanced to phase 3 trials in this space and are addressing all aspects of the disease: inflammation, pain, and regeneration.
What industry does Paradigm Biopharmaceuticals Limited operate in?
Paradigm Biopharmaceuticals Limited, trading as Paradigm Biopharma, is a Public Company that generates the majority of its income from the Pharmaceutical Product Manufacturing industry in Australia.
Where is Paradigm Biopharmaceuticals Limited located?
Murray Cod Australia Limited company is based at 500 Collins Street, Melbourne, Victoria, Australia.
Who is the CEO of Paradigm Biopharmaceuticals Limited?
The Chairman & Managing Director of Paradigm Biopharmaceuticals Limited is Paul Rennie and the Chairman & Managing Director is Paul Rennie.
What was Paradigm Biopharmaceuticals Limited’s revenue in 2025?
In 2025, Paradigm Biopharmaceuticals Limited generated total revenue of approximately $6.9 million.
Cut through the noise with intelligence you can trust
